Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Collaboration Deal to Speed New Drug Development

By Mike Botta | March 7, 2016

Cambridge, MA – Novartis has signed a collaboration agreement with clinical data network TriNetX giving its researchers access to real-time data to support clinical study and protocol design, site selection, and patient recruitment.

Novartis through its pharmaceutical division develops patent-protected medicines for commercialization in oncology, primary care and specialty care.

The TriNetX proprietary network includes healthcare providers, pharmaceutical companies and contract research organizations around the world, enabling researchers to locate patients at sites for clinical trials.

Available data includes demographic, diagnosis, procedure, medication, and laboratory test information. Analytics modules provide critical detail on the criteria and new patient rate.

Anonymized data can be traced to healthcare providers who identify individual patients, allowing researchers to develop virtual patients that share common characteristics for recapitulation in real world clinical trial settings.

“Our mission is to disrupt the clinical trial design space by unleashing the power of data that is currently locked away,” Gadi Lachman, TriNetX CEO, said. “Through our network, healthcare providers, pharma and contract research organizations can create strategic partnerships to improve clinical research and patient care.”

Lachman called the collaboration agreement with Novartis “a win-win” for the two companies, member institutions, and ultimately patients.

Novartis focuses its business on three divisions: pharmaceuticals, eye care and generics. The divisions are supported by the Novartis Institutes for BioMedical Research (NIBR) and a centralized services group to facilitate collaboration across divisions.

The NIBR network research institutes encourage teams and individuals to work across institutional and geographic boundaries, according to the company. NIBR is based in Cambridge, MA.

(Sources: TriNetX, Novartis)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE